Pharmacyclics, Inc. - Product Pipeline Review - Q4 2010

GlobalData, November 2010, Pages: 64

Pharmacyclics, Inc. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Pharmacyclics, Inc. - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Pharmacyclics, Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Pharmacyclics, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Pharmacyclics, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Pharmacyclics, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Pharmacyclics, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Pharmacyclics, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Pharmacyclics, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Pharmacyclics, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Pharmacyclics, Inc. and identify potential opportunities in those areas.

List of Tables
List of Figures
Pharmacyclics, Inc. Snapshot
Pharmacyclics, Inc. Overview
Key Information
Key Facts
Pharmacyclics, Inc. – Research and Development Overview
Key Therapeutic Areas
Pharmacyclics, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Pharmacyclics, Inc. – Pipeline Products Glance
Pharmacyclics, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Pharmacyclics, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Pharmacyclics, Inc. – Drug Profiles
Motexafin Gadolinium + Taxotere
Product Description
Mechanism of Action
R&D Progress
PCI-24781
Product Description
Mechanism of Action
R&D Progress
PCI-27483
Product Description
Mechanism of Action
R&D Progress
Xcytrin + Zevalin
Product Description
Mechanism of Action
R&D Progress
Xcytrin-
Product Description
Mechanism of Action
R&D Progress
Motexafin Gadolinium + Taxotere
Product Description
Mechanism of Action
R&D Progress
PCI-24781
Product Description
Mechanism of Action
R&D Progress
PCI-32765
Product Description
Mechanism of Action
R&D Progress
CRA-026440
Product Description
Mechanism of Action
R&D Progress
PCI-45261
Product Description
Mechanism of Action
R&D Progress
PCI-45292
Product Description
Mechanism of Action
R&D Progress
PCI-34051
Product Description
Mechanism of Action
R&D Progress
Pharmacyclics, Inc. – Pipeline Analysis
Pharmacyclics, Inc. – Pipeline Products by Therapeutic Class
Pharmacyclics, Inc. Pipeline Products By Target
Pharmacyclics, Inc. – Pipeline Products by Route of Administration
Pharmacyclics, Inc. – Pipeline Products by Molecule Type
Pharmacyclics, Inc. - Dormant Projects
Pharmacyclics, Inc. – Company Statement
Pharmacyclics, Inc. – Locations And Subsidiaries
Head Office
Recent Developments
Dec 06, 2009: Pharmacyclics, Inc. Reports Interim Safety And Clinical Data From A Phase I/II Clinical Trial Of Its Oral HDAC Inhibitor PCI-24781 In Lymphoma At The American Society Of Hematology Annual Meeting
Jun 05, 2009: Phase 1/2 Trial Of Motexafin Gadolinium Plus Antibody Targeted Radiation Therapy Demonstrates High Complete Response Rate In Patients With Non-Hodgkin's Lymphoma
Apr 16, 2009: Pharmacyclics Updates Positive Clinical Responses In Its PCI-24781 Clinical Program Targeting HDAC
Apr 13, 2009: Pharmacyclics Initiates Phase 1 Clinical Trial Of Novel Oral Btk Inhibitor For Refractory B-cell Non-Hodgkin's Lymphoma
Jun 09, 2008: Pharmacyclics Novel Btk Inhibitor Shows Efficacy In Preclinical Models Of Rheumatoid Arthritis And Lymphoma
Jun 09, 2008: Pharmacyclics Novel Btk Inhibitor Shows Efficacy In Preclinical Models Of Rheumatoid Arthritis And Lymphoma
Jun 05, 2008: Pharmacyclics, Inc. announces That Phase I/II Trial Of Motexafin Gadolinium Plus Antibody Targeted Radiation Therapy Demonstrates High Complete Response Rate In Patients With Non-Hodgkin's Lymphoma
Jun 05, 2008: Pharmacyclics, Inc. announces That Phase I/II Trial Of Motexafin Gadolinium Plus Antibody Targeted Radiation Therapy Demonstrates High Complete Response Rate In Patients With Non-Hodgkin's Lymphoma
Apr 15, 2008: Pharmacyclics Reports Multiple Presentations At AACR On Its HDAC And Selective HDAC Inhibitors
Apr 14, 2008: Pharmacyclics Announces Preclinical Results Supporting Development Of Its Novel Btk Inhibitor In Immune Mediated Diseases
Financial Deals Landscape
Pharmacyclics, Inc., Deals Volume Summary, 2004 to YTD 2010
Pharmacyclics, Inc., Deals Summary By Region, 2004 to YTD 2010
Pharmacyclics, Inc., Deals Summary, 2004 to YTD 2010
Pharmacyclics, Inc. Detailed Deal Summary
Asset Purchase
Pharmacyclics Acquires Cancer Drug Candidates And Intellectual Property From Celera Genomics
Equity Offering
Pharmacyclics Completes Rights Offering Of $29 Million
Pharmacyclics Completes Private Placement Of $1 Million
Pharmacyclics Completes Underwritten Public Offering Of $22.74 Million
Pharmacyclics Completes Underwritten Public Offering Of $42 Million
Pharmacyclics Enters Into Collaboration With Servier
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Customers who bought this item also bought

• eLEARNING - Global Strategic Business Report
• Charter Schools - Global Outlook
• Aerospace and Defense Industry - Global Strategic Business Report
• Education Services - Global Strategic Business Report
• Commercial And Military Flight Simulation - Global Strategic Business Report
• Sports and Fitness Nutrition - Global Strategic Business Report
• North America – Smart Weapons Markets and Technologies Outlook – 2013-2020
• Private Tutoring - Global Strategic Business Report
• Biodefense Industry - Market to Benefit from Federal Funding such as the BIO EDEP Fund to Support Security Plans
• Defense Robotics - Global Strategic Business Report